A BCL6 rearrangement test looks for a structural change involving the BCL6 gene on chromosome 3. BCL6 normally helps germinal-center B cells grow, change their antibody genes, and avoid premature maturation. When BCL6 is moved next to a different regulatory region, its activity may remain switched on at the wrong time and contribute to lymphoma.
The test is most often used in diffuse large B-cell lymphoma, high-grade B-cell lymphoma, selected follicular lymphomas, and other germinal-center B-cell tumors. Fluorescence in situ hybridization, or FISH, is the usual method, although chromosome analysis and next-generation sequencing can also detect the change. A positive result does not diagnose a lymphoma by itself and does not have one universal prognostic meaning. Its significance depends on the lymphoma type, cell appearance, immunophenotype, BCL6 partner, and whether MYC or BCL2 is also rearranged. BCL6 protein staining is a separate test and cannot substitute for a rearrangement study.
- A positive BCL6 rearrangement shows that the BCL6 gene has been structurally altered in the tested tumor cells.
- BCL6 rearrangement is common in diffuse large B-cell lymphoma but is not specific to one lymphoma diagnosis.
- A MYC and BCL6 double rearrangement is not classified identically to MYC and BCL2 double-hit lymphoma in all current systems.
- BCL6 protein positivity on immunohistochemistry does not prove a BCL6 gene rearrangement.
- A negative result does not rule out lymphoma, because many BCL6-driven tumors use other molecular mechanisms.
Table of Contents
- What a BCL6 Rearrangement Is
- Why the Test Is Ordered
- How BCL6 Testing Is Performed
- How to Interpret the Results
- BCL6 in Diffuse Large B-Cell Lymphoma
- MYC/BCL6 Double-Rearranged Lymphoma
- Prognosis and Treatment Implications
- Limitations and Next Steps
What a BCL6 Rearrangement Is
BCL6 encodes a transcriptional repressor, a protein that turns groups of genes down or off. It is essential during the germinal-center reaction, the stage in lymph nodes when activated B cells rapidly divide and refine their antibodies. BCL6 temporarily suppresses DNA-damage responses and differentiation so these cells can complete that process. Normal cells later reduce BCL6 activity and mature into memory B cells or plasma cells.
A rearrangement breaks DNA near BCL6 at chromosome band 3q27 and joins it to another genomic region. The partner may be an immunoglobulin gene, such as IGH, IGK, or IGL, or one of many non-immunoglobulin genes. The partner’s regulatory elements can keep BCL6 active when it should be silenced. Reports may use terms such as “BCL6 rearrangement detected,” “3q27 rearrangement,” or a named fusion such as IGH::BCL6.
BCL6 rearrangements are somatic, meaning they arose in the lymphoma clone. They are not generally inherited and do not imply that children or siblings carry the same change. This differs from a germline genetic test, which examines inherited DNA and may have implications for relatives.
The rearrangement is not unique to one disease. It occurs in a substantial minority of diffuse large B-cell lymphomas and in some high-grade B-cell lymphomas, follicular lymphomas, and other mature B-cell neoplasms. Its frequency and biological role vary with the lymphoma’s molecular subtype. Some rearrangements arise early in tumor development, while others appear during progression or transformation.
BCL6 gene status must also be separated from BCL6 protein expression. Immunohistochemistry can show that lymphoma cells contain BCL6 protein and helps identify a germinal-center phenotype. Many BCL6-positive tumors have no rearrangement, because mutations, copy-number changes, signaling pathways, or normal cell-of-origin programs can produce the protein. Conversely, technical factors or unusual biology can make protein staining weak despite a rearrangement.
The exact partner may add biological information. Immunoglobulin partners can produce high BCL6 expression, while non-immunoglobulin partners may place BCL6 under different regulatory control. Routine break-apart FISH confirms that BCL6 is disrupted but usually does not name the partner. Broader sequencing may be needed when that detail is clinically or diagnostically important.
Why the Test Is Ordered
BCL6 rearrangement testing is ordered when a pathologist needs to classify an aggressive or germinal-center B-cell lymphoma more precisely. It is rarely interpreted as a stand-alone test. The decision often follows review of biopsy architecture, cell size, growth pattern, immunohistochemistry, flow cytometry, and clinical findings.
Common reasons include:
- Newly diagnosed diffuse large B-cell lymphoma
- High-grade morphology, blastoid cells, or a very high Ki-67 proliferation index
- A germinal-center B-cell immunophenotype
- A MYC rearrangement that prompts testing for BCL2 and BCL6
- Suspected double-hit or triple-hit lymphoma
- Grade 3 or otherwise unusual follicular lymphoma
- Follicular lymphoma that lacks the typical BCL2 rearrangement
- Suspected transformation from an indolent lymphoma to an aggressive lymphoma
- A limited biopsy whose features overlap several entities
Many laboratories use a panel of MYC, BCL2, and BCL6 FISH probes for large B-cell lymphomas. Others screen with morphology and immunophenotype before ordering FISH. Broad testing reduces the chance of missing an important combination, but local practice differs because cost, tissue availability, turnaround time, and classification policy vary.
Testing BCL6 is particularly important after a MYC rearrangement is found. A concurrent BCL2 rearrangement defines a recognized MYC/BCL2 double-rearranged category. A concurrent BCL6 rearrangement creates a different and more heterogeneous group whose placement differs between current lymphoma classifications. Knowing all three results prevents the vague term “double-hit” from hiding biologically distinct diseases.
In follicular-pattern lymphomas, BCL6 testing can help evaluate cases that do not fit conventional BCL2-rearranged follicular lymphoma. Some BCL6-rearranged follicular lymphomas have higher-grade features or unusual immunophenotypes. However, the test cannot replace assessment of follicular architecture, centrocytes and centroblasts, CD10, BCL2, BCL6, and other markers.
The test is not a screening assay for people without a diagnosed or suspected lymphoma. BCL6 alterations are evaluated in tumor tissue, not used to predict inherited cancer risk. Enlarged lymph nodes, fevers, night sweats, or weight loss require clinical evaluation and often tissue sampling before molecular testing becomes useful.
A repeat study may be appropriate if lymphoma returns after a long remission, changes behavior, or appears to transform. Tumor clones evolve, and a later biopsy can acquire rearrangements that were absent or below detection in the original sample. Repeat testing is most informative when the new tissue represents the active disease and the result could change classification or treatment.
How BCL6 Testing Is Performed
Fluorescence in situ hybridization
FISH is the most common BCL6 rearrangement method. A break-apart assay uses two differently colored probes positioned on opposite sides of BCL6. In an intact gene, the colors overlap or sit very close together. A rearrangement separates them, creating a split-signal pattern. The laboratory counts abnormal and normal nuclei and applies a validated cutoff.
Break-apart FISH detects many partner genes without needing to know the partner in advance. It is well suited to formalin-fixed, paraffin-embedded biopsy tissue. It may also be performed on fresh cells, bone marrow, cytology cell blocks, or other validated specimens. A FISH test for gene rearrangements is targeted, so it does not provide a complete tumor profile.
A positive percentage is not a measure of how aggressive the lymphoma is or how likely treatment is to work. It reflects how many countable nuclei showed the probe pattern in that specimen. Tumor purity, normal cells, sectioning artifacts, and cutoff rules influence the number. Borderline findings may require a second reader, another block, or a different method.
Chromosome analysis
Conventional karyotyping examines chromosomes in dividing cells. It can reveal a translocation involving 3q27 and show other abnormalities in the same clone. Its broad view is valuable, but it requires viable cells that grow in culture. Fixed tissue cannot be cultured, and some lymphoma cells divide poorly outside the body. Small or cryptic rearrangements may also be missed.
Next-generation sequencing
DNA- or RNA-based next-generation sequencing can detect structural variants, identify the partner, and provide mutations or copy-number changes at the same time. RNA sequencing shows an expressed fusion transcript, while DNA sequencing maps the genomic breakpoint. Performance depends heavily on panel design. BCL6 has a broad breakpoint region, so a panel with limited intronic coverage may return a false-negative result.
A tumor genomic test may answer more questions than FISH, but it is not automatically more sensitive for every rearrangement. Laboratories often use FISH and sequencing as complementary tools.
Immunohistochemistry and other companion studies
Immunohistochemistry for BCL6 protein helps classify the tumor’s cell of origin and supports diagnoses such as follicular lymphoma. It does not test the gene arrangement. MYC and BCL2 protein stains identify a double-expressor phenotype, which is also different from double-hit genetics. Flow cytometry evaluates cell-surface markers and clonality but does not directly detect BCL6 rearrangements.
Most patients need no preparation for the molecular analysis itself. Preparation concerns the biopsy procedure, such as fasting for sedation or managing blood-thinning medicines under medical direction. Results commonly take several days to two weeks. Complex cases may take longer when tissue must be retrieved, additional probes are added, or an outside expert reviews the case.
How to Interpret the Results
A complete report should state the method, specimen, result, percentage or signal pattern when appropriate, laboratory cutoff, and any technical limitations. The final diagnosis should integrate the molecular result with pathology rather than present it as an isolated fact.
| Reported result | Usual meaning | Important caution |
|---|---|---|
| BCL6 rearrangement detected | A structural change involving BCL6 is present in the tested tumor population. | It does not identify one lymphoma type or prognosis by itself. |
| BCL6 rearrangement not detected | No rearrangement was found above the assay’s detection threshold. | Lymphoma and BCL6 protein expression can still be present. |
| Equivocal or borderline | The signal percentage or pattern does not support a confident call. | Repeat counting, another block, or another method may be needed. |
| Failed or insufficient | The sample did not meet technical quality requirements. | This is not a negative biological result. |
A positive result should trigger several follow-up questions. Which lymphoma entity does the morphology support? Were MYC and BCL2 also tested? Does sequencing identify a partner? Is the rearrangement present alone or with other high-risk alterations? Has the pathologist distinguished a gene rearrangement from protein expression?
A negative result means the assay did not find a qualifying split or fusion in that sample. It cannot exclude diffuse large B-cell lymphoma, follicular lymphoma, or high-grade lymphoma. It may also miss a low-level clone, a breakpoint outside probe coverage, or a rearrangement obscured by poor tissue quality. The report’s adequacy statement is therefore as important as the word “negative.”
An atypical FISH pattern may show extra copies, loss of one probe, or complex signals. These can reflect copy-number gain, deletion, an unbalanced rearrangement, polyploidy, or technical artifact. Such patterns may need correlation with chromosome analysis or sequencing. “Abnormal” does not always equal “rearranged,” and the laboratory should explain which criteria were met.
If a report says “BCL6 positive,” ask whether it refers to immunohistochemistry or FISH. Protein positivity is often expressed as a percentage of stained tumor cells. FISH positivity describes a DNA signal pattern. Those results answer different questions and should never be substituted for one another.
The result does not establish an inherited condition. Routine testing of relatives is not indicated because of a somatic BCL6 rearrangement. If the patient’s personal or family history independently suggests hereditary cancer, that question requires a separate genetics assessment and usually a non-tumor DNA sample.
BCL6 in Diffuse Large B-Cell Lymphoma
Diffuse large B-cell lymphoma, or DLBCL, is a broad group of aggressive lymphomas rather than one molecular disease. BCL6 rearrangements occur in roughly one quarter to one third of cases in many series, although rates vary by population, testing strategy, and subtype. They appear in both germinal-center B-cell-like and activated B-cell-like biological groups, with different partner patterns.
A BCL6 rearrangement alone does not create a separate routine DLBCL diagnosis. The tumor may still be classified as DLBCL, not otherwise specified, or another defined entity after all features are considered. Modern classifications increasingly use combinations of morphology, immunophenotype, rearrangements, and mutation profiles rather than allowing one marker to dominate.
The cell-of-origin category adds context. Gene-expression profiling is the reference molecular approach, while immunohistochemical algorithms provide an approximation. BCL6 protein is part of some algorithms, but protein staining does not reveal BCL6 rearrangement status. A tumor can be BCL6-rearranged yet fall outside the germinal-center category, particularly when the partner and broader molecular program differ.
BCL6 rearrangement can also emerge during transformation of follicular lymphoma or another indolent B-cell neoplasm. Comparison with prior tissue, including immunoglobulin clonality and shared mutations, may show whether the large-cell lymphoma evolved from the earlier disease. Transformation often carries more clinical significance than the rearrangement alone.
Prognostic studies have produced conflicting results. Some associate BCL6 rearrangement with poorer survival, while others find little independent effect after accounting for age, stage, treatment, cell of origin, MYC, BCL2, and other molecular factors. Differences in probe design and whether immunoglobulin and non-immunoglobulin partners were separated may help explain the inconsistency.
For this reason, a patient should not be told that a positive BCL6 result automatically means a good or poor outcome. Standard prognostic tools still include stage, lactate dehydrogenase, performance status, extranodal sites, age, bulk, and early treatment response. Molecular features refine that estimate but do not replace the full clinical picture.
MYC/BCL6 Double-Rearranged Lymphoma
A lymphoma with rearrangements of both MYC and BCL6 is often called MYC/BCL6 double-rearranged or, informally, double-hit. The informal term can cause confusion because MYC/BCL6 tumors differ from MYC/BCL2 double-rearranged lymphomas in morphology, molecular profile, and classification.
The fifth edition of the World Health Organization classification reserves the specific entity of DLBCL/high-grade B-cell lymphoma with MYC and BCL2 rearrangements for MYC/BCL2 cases. MYC/BCL6-only tumors are generally classified according to their morphology as DLBCL, not otherwise specified, or high-grade B-cell lymphoma, not otherwise specified. The International Consensus Classification retains a provisional category for high-grade B-cell lymphoma with MYC and BCL6 rearrangements. A pathology report may therefore mention which system it follows.
This difference is not merely wording. MYC/BCL2 double-rearranged lymphomas commonly have a germinal-center phenotype and a characteristic molecular background. MYC/BCL6 cases are more heterogeneous. Some resemble DLBCL with activated B-cell biology, some have germinal-center features, and some carry additional alterations that drive behavior.
Triple-rearranged tumors contain MYC, BCL2, and BCL6 rearrangements. Current systems generally group many of these with MYC/BCL2 double-rearranged lymphoma because the MYC/BCL2 combination is present, but pathology details remain important. A report should list all detected rearrangements rather than relying only on “triple hit.”
Double rearrangements must be demonstrated by a genomic method. MYC and BCL6 protein coexpression does not establish them. Likewise, a MYC rearrangement plus BCL6 protein positivity is not a MYC/BCL6 double rearrangement. This distinction affects classification, risk discussion, and sometimes treatment planning.
When a MYC rearrangement is detected, testing should clarify its partner if possible. MYC::IGH and non-IGH MYC partners may have different associations, although partner-specific findings are not always reported by break-apart FISH. Broad molecular profiling can add context, but it should not delay urgent treatment when the clinical situation is rapidly progressing.
Prognosis and Treatment Implications
BCL6 rearrangement is primarily a diagnostic and classification biomarker, not a direct prescription for one drug. There is no broadly approved therapy selected solely because BCL6 is rearranged. Treatment follows the integrated lymphoma diagnosis, stage, symptoms, patient fitness, prior therapy, and other biomarkers.
For ordinary DLBCL, common first-line therapy uses an anti-CD20 antibody with multiagent chemotherapy, with regimen choice guided by current clinical standards and patient factors. A BCL6 rearrangement alone does not automatically require intensified therapy. Clinicians may consider a more detailed risk discussion when MYC or BCL2 is also rearranged, but evidence for the best regimen in MYC/BCL6 disease remains less definitive than the terminology sometimes suggests.
Patients with MYC/BCL2 double-rearranged lymphoma often receive specialized evaluation because the disease has a higher risk of treatment failure and central nervous system involvement. MYC/BCL6-only disease should not automatically be assumed to carry the identical risk. Its prognosis varies, and current studies support viewing it as a heterogeneous category.
BCL6 protein and its regulatory pathway are being studied as therapeutic targets. Experimental approaches include BCL6 degraders, transcriptional inhibitors, and combinations that disrupt cooperating survival pathways. These are research strategies rather than routine consequences of a positive clinical FISH result. Eligibility usually depends on a trial’s full criteria, not BCL6 rearrangement alone.
Response assessment uses clinical examination, blood tests, and imaging, commonly PET/CT for FDG-avid lymphoma. End-of-treatment metabolic response often provides more immediate prognostic information than an isolated baseline BCL6 result. A new or growing lesion should be biopsied when feasible if relapse, transformation, infection, or another cancer could explain it.
The treating team should receive the final molecular addendum before important regimen decisions whenever possible. If therapy must begin urgently, the team may start a reasonable provisional regimen and adjust after classification is complete. Clear communication between hematopathology, oncology, radiology, and the patient reduces the risk that a late FISH result is overlooked.
Limitations and Next Steps
BCL6 testing is limited by both specimen quality and biology. A small core can miss a transformed focus. Necrosis, crush artifact, low tumor content, and harsh bone-marrow decalcification can damage nuclei or nucleic acids. FISH examines only the targeted region, while sequencing can miss rearrangements if its capture design does not cover the breakpoint.
Tumor heterogeneity can produce discordant results between sites or time points. One lymph node may contain an indolent component and another an aggressive clone. A result from an old biopsy may not describe a new relapse. Repeat biopsy is most valuable when disease behavior has changed or the result would affect management.
Before acting on the report, ask:
- What is the final integrated lymphoma diagnosis?
- Was BCL6 tested by break-apart FISH, fusion FISH, karyotype, or sequencing?
- Were MYC and BCL2 rearrangements tested on the same specimen?
- Does “BCL6 positive” refer to the gene or the protein?
- Was the specimen adequate, and how many tumor cells were present?
- Is the result classified under WHO fifth edition, ICC, or both?
- Does the result alter the recommended regimen, clinical-trial options, or CNS evaluation?
- Would review at a lymphoma referral center change interpretation?
An expert hematopathology review can help when the specimen is limited, morphology is unusual, FISH patterns are borderline, or reports use outdated double-hit terminology. Review should include original slides, immunostains, flow-cytometry data, probe details, and relevant clinical history. Repeating every test is unnecessary when the original work was technically sound, but targeted confirmation can resolve a meaningful discrepancy.
Urgent symptoms come from the lymphoma, not from the laboratory result itself. Rapidly enlarging neck or chest masses, breathing or swallowing difficulty, new weakness, severe abdominal pain, confusion, or signs of tumor lysis after treatment need prompt medical attention. Fever during chemotherapy may also require immediate evaluation because infection can become serious quickly.
The clearest interpretation is a sentence that connects the finding to the disease: for example, “DLBCL with a BCL6 rearrangement and no MYC or BCL2 rearrangement,” rather than simply “BCL6 positive.” That wording prevents protein stains, rearrangements, and double-hit categories from being mixed together and gives the oncology team a usable diagnosis.
References
- The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee 2022 (Position Statement)
- Mature B, T and NK-cell, plasma cell and histiocytic/dendritic cell neoplasms: the fifth edition of the WHO classification of haematolymphoid tumours 2024 (Review)
- B- and T-/NK-Cell Lymphomas in the 2022 International Consensus Classification of Mature Lymphoid Neoplasms and Comparison with the WHO Fifth Edition 2024 (Review)
- Diffuse large B-cell lymphoma 2025 (Review)
- Diffuse Large B-Cell Lymphoma/High-Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements: Gene Expression Profiling, Mutational Landscape, and Clinical Outcomes 2025
- High-Grade B-Cell Lymphomas: Pathologic and Molecular Characteristics, Classification, and Treatment 2025 (Review)
Disclaimer
This article is for education and does not replace an integrated diagnosis from a hematopathologist or treatment advice from a hematologist-oncologist. BCL6 rearrangement results must be interpreted with morphology, immunophenotype, MYC and BCL2 testing, specimen quality, stage, and the patient’s overall health. Seek urgent care for breathing difficulty, neurologic symptoms, severe pain, rapidly worsening swelling, or fever during chemotherapy.
